Interferon alfa-2a is a cytokine produced by recombinant DNA techniques and has antiproliferative, antiviral and immunomodulating effects. A number of case reports in the past have suggested relative safety of alpha-interferons during pregnancy with little or no effect on the fetus. A 15-year-old adolescent became pregnant while receiving alpha-interferon for essential thrombocythemia. She delivered a small-for-gestational age baby girl at 33 weeks gestation. The infant displayed a facial rash characteristic of neonatal lupus and transient thrombocytopenia; maternal and neonatal serologies were typical for drug-induced lupus. These findings suggest probable association between maternal use of alpha interferon and adverse effects in the fetus.
INTRODUCTION
Essential thrombocythemia (ET) during pregnancy is known to cause obstetric complications including increased first trimester spontaneous abortions and still births. [1] [2] [3] Most of these complications are attributed to placental thrombosis, infarction, or hemorrhage. 4 A number of case reports have suggested relative safety of alpha interferons during pregnancy with little or no effect on the fetus. 1 We describe intrauterine growth-restriction (IUGR), thrombocytopenia, and neonatal drug-induced lupus in a newborn whose mother received alpha-interferon for ET during pregnancy.
CASE REPORT
The infant's mother was initially evaluated in St. Louis Children's Hospital at 10 years of age with acute onset chorea, splenomegaly and thrombocytosis (platelet count of 1.5 million/cumm). Her antistreptolysin O titer was elevated at 1:625 (normal <320) and throat culture was negative. A diagnosis of rheumatic chorea was made and she was started on penicillin prophylaxis. The movement disorder improved over time. Bone marrow biopsy displayed increased myeloid to erythroid ratio of 4:1, but no other abnormality.
Repeat bone marrow biopsy performed 18 months later showed myeloid hyperplasia with normal cytogenetics. Southern blot and polymerase chain reaction of her marrow DNA showed bcr-abl fusion gene and a diagnosis of chronic myelogenous leukemia (CML) was made. This gene rearrangement typically underlies t(9;22) translocation in CML; 5 however, this finding may also be seen as a normal genetic variation without CML, as was later shown from a skin biopsy in this patient. Hence her initial diagnosis of CML was revised to ET. In view of worsening splenomegaly and persistent thrombocytosis (platelets >1 million/ mm 3 ), she was started on alpha-interferon (Roferon s ) at 2.5 Â 10 6 U/m 2 /day. When alpha-interferon dose was increased to 5 Â 10 6 U/m 2 /day, she developed neutropenia (absolute neutrophil count below 1000/mm 3 ). Finally, she was maintained at the dose of 4 Â 10 6 U/m 2 /day with normal platelet counts (range 350,000 to 450,000/mm 3 ), partial regression of splenomegaly and normal neutrophil count.
At the age of 15 years, while still on alpha-interferon therapy, this patient was found to be 13 weeks pregnant. Since thrombocytosis is known to increase spontaneous abortion, 6 extensive literature review revealed no reported adverse effect in fetus with maternal alpha-interferon therapy. Therefore, we continued alpha-interferon therapy during her pregnancy. Other medications were Penicillin, multivitamins and iron. She was treated for gonococcal infection during the first trimester and urinary tract infection at 7 months of gestation. Her blood group was B þ , antibody screen negative, RPR nonreactive, rubella immune, hepatitis B negative, HIV negative, there was no history of substance abuse and urine drug screen negative. Group B a-hemolytic streptococcus was not tested (as the routine practice was to test at 36 weeks gestation), and serum AFP, b-HCG and unconjugated estrogen level were normal.
Fetal ultrasound at 31 weeks revealed normal amniotic fluid index (AFI) of 101 mm, and estimated fetal weight of 1272 g (<10th centile). Repeat fetal ultrasound at 33-3/7 weeks showed reduced AFI at 24 mm and estimated fetal weight of 1463 g (<10th centile). At 33-5/7 weeks of gestation, labor was induced for oligohydramnios and suspected IUGR. The mother's prepregnancy weight was 140 lbs and height 5 0 5 00 ; at delivery, her weight was 162 lbs. She delivered a vigorous female infant via cesarean section after failure to progress and decreased fetal heart tones. The baby's birth weight was 1465 g (3rd centile); her length was 42 cm (10th percentile) and occipital-frontal circumference was 28 cm (3rd centile). Physical examination showed a palpable spleen and petechial rash in otherwise a well-appearing infant. Day of life 1 (DOL1) infant's blood work showed white cell count of 15,300/mm 3 , hemoglobin of 21.8 g/day and platelet count of 48,000/mm 3 .
Although her blood culture remained negative, she received 7-days course of ampicillin and gentamicin for presumed sepsis. Her platelet count reached a nadir of 33,000/mm 3 before it spontaneously returned to normal levels (112,000/mm 3 on DOL7 and 226,000/mm 3 on DOL12). Head ultrasound demonstrated bilateral grade I intraventricular hemorrhages. Toxoplasma serology (<1:16 IgG), and urine CMV were negative, RPR nonreactive and there was no chorioretinitis on ophthalmic examination. Placenta weighted 210 g (<10th percentile). Placental pathology showed a normal three vessel umbilical cord, normal fetal membranes, no umbilical cord vascular thrombosis, torsion or placental infarction. The infant was treated with phototherapy for hyperbilirubinemia (peaked at 15.1 mg/dl with direct fraction of 0.1 on DOL2).
On DOL11, infant developed a red weepy rash over the cheeks and nasal bridge in a malar distribution and made worse by phototherapy. It was associated with an elevated ANA titer of 1:320 with speckled immunofluorescent pattern and a positive Ro (anti SS-A) antibody consistent with neonatal lupus. 7 Anti-Ro and anti-La antibodies most commonly give a nuclear speckled pattern. The rash cleared with a 1% topical hydrocortisone ointment therapy. A 12 lead EKG did not show evidence of heart block. The infant showed good postnatal growth and at 4 months, her weight was 5.32 kg (between 25 and 50th centile), length 59.1 cm (50th centile) and head circumference 39.5 cm (25 to 50th centile). Maternal ANA titer after child birth was elevated (1:640, speckled pattern), returning to normal 3 months after delivery (1:40, speckled), but SS-B (La) and SS-A (Ro) were still positive.
DISCUSSION
There is great interest in exploring safe therapeutic options for the mother and the fetus to manage pregnancy associated with ET. Treatment modalities include busulfan, anagrelide, platletpheresis and alpha-interferon. Busulfan is a known teratogen and anagrelide is known to cross placenta and cause thrombocytopenia. Platletpheresis is a viable option, however labor is intensive as well as not effective beyond the short term. 2, 8 Alpha-interferon, on the other hand, has not been linked with significant fetal malformations, adverse fertility or clinical effect and has been used during pregnancy (see below).
Pons et al. 9 described two HIV-positive women who were injected with alpha-interferon with the intention of therapeutic abortion 24 hours prior to abortion. These researchers measured the serum alpha-interferon level in maternal, fetal blood and amniotic fluid concentrations at 1 and 4 hours postinjection. Despite high maternal levels, the fetal alpha-interferon level was essentially undetectable. Haggstrom et al., 10 reported virtually undetectable alpha-interferon levels in the two infants born to mothers being treated for CML.
Although the above evidence suggests that alpha-interferon does not cross placenta during human pregnancy, it may exert an indirect effect on unborn fetus. Drug-induced lupus disease and other autoimmune disorders have been described in hepatitis C or cancer patients treated with recombinant alpha-interferon. 11 Likewise, lupus is known to complicate pregnancy by increasing spontaneous abortion, causing premature rupture of membranes, oligohydramnios, pre-eclampsia, maternal HELLP syndrome, fetal distress and IUGR. 12 Neonatal lupus erythematosus is a model of passively acquired autoimmune disease seen in infants born to mothers who have anti-SS-A/Ro or anti-SS-B/La antibodies. 13 Clinical features of neonatal lupus syndrome can be transient and include photosensitive discoid rash, cytopenias, hepatosplenomegaly, myocarditis, pericarditis. It can also give serious and permanent structural changes like complete heart block, and endomyocardial fibroelastosis. 7 Our infant in this report did not have evidence of cardiac disease, however she developed the photosensitive rash, thrombocytopenia and characteristic maternal-neonatal serologies typical for neonatal lupus erythematosus.
Harrison 4 summarized 220 reported pregnancies in women with ET with successful outcomes in 59%. Spontaneous remissions, uncomplicated successful pregnancies, in addition to high incidences of recurrent miscarriage, intrauterine death, placental abruption, growth retardation, premature delivery and pre-eclampsia have been described. The most common major complication encountered is first trimester miscarriage in 29% of cases, slightly greater than the 15 to 20% rate of first trimester loss anticipated. The presence of placental infarcts in ET is a clue to the pathogenesis of this process.
In a review of the literature Hiratsuka et al. 1 identified 27 pregnancies born to mothers who treated with alpha-interferon. Four women (15%) gave birth prematurely and six infants (22%) were affected by IUGR. However, no congenital malformations were observed. Growth restriction has been also documented in newborn Swiss mice exposed to alpha-interferon in utero.
1 Additionally, there is some evidence of an abortifacient effect when administered in high doses to rhesus monkeys. 8 One of the clinical indications for using alpha-interferon is its apparent antiangiogenic activity in hemangiomas and other vascularized tumors. In a study by von Marschall et al., 14 alphainterferon was found to inhibit vascular endothelial growth factor gene transcription in neuroendocrine tumors thus leading to a decrease in angiogenesis. It is conceivable that alpha-interferon might affect appropriate angiogenesis during placental formation. Although none of the cases in the literature have reported placental size, it is possible that some of the reported infants with IUGR may have been small secondary to placental insufficiency. Likewise, the small placental size in this patient might be related to intrapartum alpha-interferon exposure and possibly contributed to IUGR; however potential contribution from gonococcal infection and UTI during pregnancy cannot be ruled out.
Only limited information is available on safety of alphainterferon use during pregnancy. This infant displayed neonatal lupus, thrombocytopenia, IUGR and a small placenta. The mother had not been previously diagnosed with systemic lupus erythematosus. Maternal and neonatal serologies and baby girl's clinical presentation are characteristic of drug-induced lupus and alpha-interferon is the probable cause. IUGR has been described in infants born to mother receiving alpha-interferon therapy during pregnancy. To our knowledge, this is the first documented case of neonatal drug-induced lupus in a mother receiving alphainterferon therapy during pregnancy. Careful consideration should be given before alpha-interferon treatment is offered to patients with ET during early pregnancy.
